HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bourgeade, M. F. Articles by Merigan, T. C. Search for Related Content PubMed PubMed Citation Articles by Bourgeade, M. F. Articles by Merigan, T. C. Agricola Articles by Bourgeade, M. F. Articles by Merigan, T. C.

Type I and Type II Interferons: Differential Antiviral Actions in Transformed Cells

Institut National de la Santé et de la Recherche Médicale, U.43, Hôpital St Vincent-de-Paul, 74 avenue Denfert-Rochereau, Paris 75014 France and Stanford University Medical Center, Department of Medicine, Division of Infectious Diseases, Stanford, California 94305, U.S.A.

In transformed mouse embryo cells, type II interferon had much less antiviral activity than type I interferon. In non-transformed cells, the two interferons had similar high activity. Reversal of the phenotype of Moloney sarcoma virus (MSV) transformed cells by sodium butyrate restored their sensitivity to the antiviral action of type II interferon. Additional evidence for a role of the cytoskeletal network in the action of type II interferon is that its antiviral effect is reduced by cytochalasin B, colchicine or vinblastine. MSV-transformed cells, selected for their resistance to the antiviral action of type I interferon, were sensitive to type II interferon. These differences in the effects of type I and II interferon on transformed cells are at present unexplained, but suggest that they have at least partially separate mechanisms of action.

Received 22 March 1979; accepted 14 September 1979.